Matches in SemOpenAlex for { <https://semopenalex.org/work/W2053693605> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W2053693605 endingPage "A309" @default.
- W2053693605 startingPage "A309" @default.
- W2053693605 abstract "Half of patients with systemic juvenile idiopathic arthritis (sJIA) will eventually fail to non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids. Tocilizumab (TCZ) is indicated for patients with refractory sJIA. We aimed to determine the cost and the effectiveness of adding TCZ to conventional treatment for sJIA in Mexico. We designed two decision models to compare TCZ versus placebo. In each model, two time horizons were analyzed: 12 weeks and one year. Target population consists of patients (2-19 years) with active sJIA and inadequate response to NSAIDs and corticosteroids. The dosing scheme for TCZ was based on body weight: 8 mg/kg for patients ≥30 kg and 12 mg/kg for patients <30 kg. The analysis was performed under the perspective of the public health care system in Mexico. Tocilizumab acquisition cost, infusion fees and standard management of sJIA according to level of response were evaluated. Efficacy was defined in terms of the American College of Rheumatology Pediatric response criteria. Resource use and unit costs were gathered from local sources; efficacy was derived from two phase-3 clinical trials; increase in mortality and utility scores associated with level of response was based on literature. All costs are expressed in 2011 euros (€). A markedly higher proportion of patients achieved an ACRPedi70 response with TCZ in both children with the possibility of maintaining methotrexate (71% vs. 8%) and in those without that alternative (75% vs. 13%). The incremental cost per achieving an ACRPedi70 response was around 2400€ in both models. During base-case, the incremental cost per Quality-Adjusted Life Year (QALY) gained with TCZ ranged from 10,636€ to 10,681€. The gross domestic product per capita in Mexico during 2010 was estimated at 7048€. Results were robust to variation in all parameters. TCZ is a cost-effective option to treat sJIA in Mexico." @default.
- W2053693605 created "2016-06-24" @default.
- W2053693605 creator A5014264746 @default.
- W2053693605 creator A5032791277 @default.
- W2053693605 creator A5050807091 @default.
- W2053693605 date "2011-11-01" @default.
- W2053693605 modified "2023-10-18" @default.
- W2053693605 title "PMS39 Economic Evaluation of Tocilizumab for the Treatment of Systemic Juvenile Idiopathic Arthritis in Mexico" @default.
- W2053693605 doi "https://doi.org/10.1016/j.jval.2011.08.425" @default.
- W2053693605 hasPublicationYear "2011" @default.
- W2053693605 type Work @default.
- W2053693605 sameAs 2053693605 @default.
- W2053693605 citedByCount "1" @default.
- W2053693605 countsByYear W20536936052020 @default.
- W2053693605 crossrefType "journal-article" @default.
- W2053693605 hasAuthorship W2053693605A5014264746 @default.
- W2053693605 hasAuthorship W2053693605A5032791277 @default.
- W2053693605 hasAuthorship W2053693605A5050807091 @default.
- W2053693605 hasBestOaLocation W20536936051 @default.
- W2053693605 hasConcept C126322002 @default.
- W2053693605 hasConcept C142724271 @default.
- W2053693605 hasConcept C198451711 @default.
- W2053693605 hasConcept C204787440 @default.
- W2053693605 hasConcept C27081682 @default.
- W2053693605 hasConcept C2777077863 @default.
- W2053693605 hasConcept C2777178219 @default.
- W2053693605 hasConcept C2777575956 @default.
- W2053693605 hasConcept C2781059491 @default.
- W2053693605 hasConcept C2908647359 @default.
- W2053693605 hasConcept C535046627 @default.
- W2053693605 hasConcept C71924100 @default.
- W2053693605 hasConcept C99454951 @default.
- W2053693605 hasConceptScore W2053693605C126322002 @default.
- W2053693605 hasConceptScore W2053693605C142724271 @default.
- W2053693605 hasConceptScore W2053693605C198451711 @default.
- W2053693605 hasConceptScore W2053693605C204787440 @default.
- W2053693605 hasConceptScore W2053693605C27081682 @default.
- W2053693605 hasConceptScore W2053693605C2777077863 @default.
- W2053693605 hasConceptScore W2053693605C2777178219 @default.
- W2053693605 hasConceptScore W2053693605C2777575956 @default.
- W2053693605 hasConceptScore W2053693605C2781059491 @default.
- W2053693605 hasConceptScore W2053693605C2908647359 @default.
- W2053693605 hasConceptScore W2053693605C535046627 @default.
- W2053693605 hasConceptScore W2053693605C71924100 @default.
- W2053693605 hasConceptScore W2053693605C99454951 @default.
- W2053693605 hasIssue "7" @default.
- W2053693605 hasLocation W20536936051 @default.
- W2053693605 hasOpenAccess W2053693605 @default.
- W2053693605 hasPrimaryLocation W20536936051 @default.
- W2053693605 hasRelatedWork W189077404 @default.
- W2053693605 hasRelatedWork W1987294331 @default.
- W2053693605 hasRelatedWork W2071054988 @default.
- W2053693605 hasRelatedWork W2098703756 @default.
- W2053693605 hasRelatedWork W2736593664 @default.
- W2053693605 hasRelatedWork W2766107824 @default.
- W2053693605 hasRelatedWork W2783466784 @default.
- W2053693605 hasRelatedWork W2970100988 @default.
- W2053693605 hasRelatedWork W2996380604 @default.
- W2053693605 hasRelatedWork W4283269884 @default.
- W2053693605 hasVolume "14" @default.
- W2053693605 isParatext "false" @default.
- W2053693605 isRetracted "false" @default.
- W2053693605 magId "2053693605" @default.
- W2053693605 workType "article" @default.